Adenovirus infection and replication process in tumor cells

Adenovirus infection and replication in tumor cells refers to the use of genetically engineered adenoviruses that selectively infect and replicate within cancer cells, resulting in tumor cell lysis (oncolysis) and induction of anti-tumor immunity. Conditionally replicative adenoviruses (CRAds) are modified by deleting or mutating genes such as E1B-55K or E1A, restricting their ability to replicate in normal cells while allowing robust viral production and oncolysis in cancer cells. Notable examples include ONYX-015 and other engineered adenoviruses. Though often termed “targets” in oncolytic virotherapy literature, this is a process not a distinct molecular entity[1][2][3].

Other names

Oncolytic adenoviral replicationAdenoviral oncolysisReplication-competent adenovirus therapy

Selective replication in tumor cells due to mutations or deletions in viral genes (e.g., E1B-55K deletion, E1A modification) Cell lysis from viral replication and progeny release Induction of anti-tumor immune responses Potential expression of therapeutic transgenes (e.g., GM-CSF)[2]